Immunocontraception of captive exotic species. I. Przewalski's horses (Equus przewalskii) and banteng (Bos javanicus)

Could current fertility control methods be effective for landscape-scale management of populations of wild horses (Equus caballus) in Australia?

Context Fertility control is seen as an attractive alternative to lethal methods for control of population size and genetic diversity in managed animal populations. Immunocontraceptive vaccines have emerged as the most promising agents for inducing long-term infertility in individual animals. However, after over 20 years of scientific testing of immunocontraceptive vaccines in the horse, the scientific consensus is that their application as a sole management approach for reducing population size is not an effective strategy. Aims The purpose of this review is to evaluate currently available non-lethal fertility-control methods that have been tested for their contraceptive efficacy in Equidae, and to assess their suitability for effective management of wild (feral) horses in an Australian setting. Key results (1) Fertility-control agents, particularly injectable immunocontraceptive vaccines based on porcine zona pellucida (PZP) or gonadotrophin-releasing hormone (GnRH), can induce multi-year infertility (up to 3 years) in the horse. Some formulations require annual or biennial booster treatments. Remote dart delivery (on foot) to horses is possible, although the efficacy of this approach when applied to large numbers of animals is yet to be determined. (2) The proportion of females that must be treated with a fertility-control agent, as well as the frequency of treatment required to achieve defined management outcomes (i.e. halting population growth in the short term and reducing population size in the long term) is likely to be >50% per annum. In national parks, treatment of a large number of wild horses over such a broad area would be challenging and impractical. (3) Fertility control for wild horses could be beneficial, but only if employed in conjunction with other broad-scale population-control practices to achieve population reduction and to minimise environmental impacts. Conclusions In Australia, most populations of wild horses are large, dispersed over varied and difficult-to-access terrain, are timid to approach and open to immigration and introductions. These factors make accessing and effectively managing animals logistically difficult. If application of fertility control could be achieved in more than 50% of the females, it could be used to slow the rate of increase in a population to zero (2–5 years), but it will take more than 10–20 years before population size will begin to decline without further intervention. Thus, use of fertility control as the sole technique for halting population growth is not feasible in Australia.

How immunocontraception can contribute to elephant management in small, enclosed reserves: Munyawana population as a case study

Immunocontraception has been widely used as a management tool to reduce population growth in captive as well as wild populations of various fauna. We model the use of an individual-based rotational immunocontraception plan on a wild elephant, Loxodonta africana, population and quantify the social and reproductive advantages of this method of implementation using adaptive management. The use of immunocontraception on an individual, rotational basis stretches the inter-calving interval for each individual female elephant to a management-determined interval, preventing exposing females to unlimited long-term immunocontraception use (which may have as yet undocumented negative effects). Such rotational immunocontraception can effectively lower population growth rates, age the population, and alter the age structure. Furthermore, such structured intervention can simulate natural process such as predation or episodic catastrophic events (e.g., drought), which regulates calf recruitment within an abnormally structured population. A rotational immunocontraception plan is a feasible and useful elephant population management tool, especially in a small, enclosed conservation area. Such approaches should be considered for other long-lived, social species in enclosed areas where the long-term consequences of consistent contraception may be unknown.

Vaccines for immunological control of fertility

Vaccines have been proposed as one of the strategies for population control. Immunocontraceptive vaccines can be designed to inhibit: (1) production of gametes (sperm and egg); (2) functions of gametes, leading to blocking of fertilization; and (3) gamete outcome (pregnancy). Immunization with gonadotropin-releasing hormone coupled to different carriers has shown curtailment in the production of sperm with concomitant infertility in various species. Immunization of nonhuman primates and men with ovine follicle stimulating hormone has also resulted in reduced sperm output. Various spermatozoa-specific proteins such as FA1, PH-20, LDH-C₄, SP-10, SP-17, sp56, SPAG9, and Izumo have been proposed as candidate antigens to develop contraceptive vaccines, which have shown efficacy in inhibiting fertility in different animal models. Immunization with zona pellucida glycoproteins-based immunogens also results in curtailment of fertility in a variety of species. However, ways to overcome the observed oophoritis associated with zona proteins immunization have yet to be discovered, a necessary step before their proposal for control of human population. Nonetheless, this is a very promising approach to control wildlife animal population. Phase II clinical trials of β-human chorionic gonadotropin-based vaccine in women have established the proof of principle that it is possible to inhibit fertility without any untoward side-effects by vaccination. Further scientific inputs are required to increase the efficacy of contraceptive vaccines and establish their safety beyond doubt, before they can become applicable for control of fertility in humans.

Immunologic responses and adverse reactions to Freund's-adjuvanted porcine zona pellucida immunocontraceptives in domestic cats

A vaccine of native PZP with Freund's adjuvant has been widely used in zoo and wild ungulates, but safety in felids has not been evaluated. General health, immune response, and ovarian histology were assessed in five domestic cats vaccinated with PZP-Freund's and five cats given Freund's adjuvant alone. Peak antibody titers occurred 3 weeks after the third vaccination, and no ovarian lesions were present 6 months after vaccination. Seven cats developed extensive granulomatous reactions at injection sites, lymph nodes, and multiple visceral organs including lungs and brain. Persistent hypercalcemia and compromised renal function occurred in three cats with elevated serum calcitriol of probable macrophage origin. One cat died from an injection site sarcoma. Because of these severe adverse reactions, Freund's adjuvant is contraindicated in cats, and other adjuvants for PZP vaccines should be tested in cats for adverse reactions before use.

EFFECTS OF PORCINE ZONA PELLUCIDA IMMUNOCONTRACEPTIVES IN ZOO FELIDS

Methods of contraception are necessary for management of zoo felids; however, the most commonly used contraceptive (melengestrol acetate implant) is associated with serious adverse reactions with long-term use. Porcine zona pellucida (pZP) vaccines are promising as contraceptives, but their safety in zoo felids has not been tested. pZP vaccine was administered to 27 female felids representing 10 species, including African lion (Panthera leo), Asian leopard (P. pardus), jaguar (P. onca), tiger (P. tigris), snow leopard (P. uncia), cougar (Felis concolor), Siberian lynx (F. lynx), Canada lynx (F. canadensis), serval (F. serval), and bobcat (F. rufus), in 15 facilities. Over 6 wk, each animal received three i.m. injections of 65 microg pZP with Freund's complete adjuvant (FCA), Freund's incomplete adjuvant, or carbopol as the adjuvant. Behavioral signs of estrus were seen in 14 of the vaccinated felids. An unacceptably high incidence of adverse reactions was seen including injection site swelling, lameness, limb swelling, or abscessation (or all) in five felids after injection with FCA as the initial adjuvant. Adverse behavioral signs, including increased irritability and aggression, were seen in four felids. Six of the felids were assayed for antibodies against pZP during the 12 mo after vaccination; all showed antibody production. Antibody levels appeared to peak 1-4 mo after vaccination began, although elevated antibody levels persisted in two animals for > 12 mo after the first injection. All vaccinated felids were ovariohysterectomized 3-13 mo after vaccination. Folliculogenesis was present in all treated animals, and there was no histopathologic evidence of inflammatory damage to ovaries. Contraceptive efficacy was not specifically evaluated in this study; however, two of the three felids housed with an intact male became pregnant during the study, one of which gave birth to healthy cubs.